Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer
Suzanne J. Bakewell, Isabel Conde, Yassi Fallah, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2647-2647
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Metals in Cancer Research: Beyond Platinum Metallodrugs
Angela Casini, Alexander Pöthig
ACS Central Science (2024) Vol. 10, Iss. 2, pp. 242-250
Open Access | Times Cited: 28
Roles of reactive oxygen species in inflammation and cancer
Yunfei Yu, Shengzhuo Liu, Luchen Yang, et al.
MedComm (2024) Vol. 5, Iss. 4
Open Access | Times Cited: 21
Reactive Oxygen Species Bridge the Gap between Chronic Inflammation and Tumor Development
Weihua Yu, Yongmei Tu, Zi Long, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-22
Open Access | Times Cited: 65
Antitumor activity of ruthenium(III) complexes with [N2O2]-tetradentate Schiff base ligands
Zdravka Petrova, Teodora Mocanu, Rossen Spasov, et al.
Journal of Inorganic Biochemistry (2025), pp. 112853-112853
Closed Access
Current Developments of N-Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment
Alexia Tialiou, Jia Min Chin, Bernhard K. Keppler, et al.
Biomedicines (2022) Vol. 10, Iss. 6, pp. 1417-1417
Open Access | Times Cited: 24
Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections
Assunta D’Amato, Annaluisa Mariconda, Domenico Iacopetta, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1729-1729
Open Access | Times Cited: 14
ACE2-independent SARS-CoV-2 virus entry through cell surface GRP78 on monocytes – evidence from a translational clinical and experimental approach
Bing Han, Yibing Lv, Dominique Moser, et al.
EBioMedicine (2023) Vol. 98, pp. 104869-104869
Open Access | Times Cited: 13
The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation
Dina Baier, Theresa Mendrina, Beatrix Schoenhacker‐Alte, et al.
Advanced Science (2023) Vol. 10, Iss. 32
Open Access | Times Cited: 12
Roles of SIRT6 in kidney disease: a novel therapeutic target
Xueyan Yang, Jun Feng, Wei Liang, et al.
Cellular and Molecular Life Sciences (2021) Vol. 79, Iss. 1
Closed Access | Times Cited: 29
Curcumin sensitizes carboplatin treatment in triple negative breast cancer through reactive oxygen species induced DNA repair pathway
Genjin Wang, Peng Duan, Zhengkuo Wei, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 4, pp. 3259-3270
Closed Access | Times Cited: 21
The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition
Dmytro Havrylyuk, David K. Heidary, Edith C. Glazer
Biomolecules (2024) Vol. 14, Iss. 4, pp. 441-441
Open Access | Times Cited: 3
Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models
István Kacsir, Adrienn Sipos, Attila Bényei, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 813-813
Open Access | Times Cited: 17
Half sandwich-type osmium, ruthenium, iridium and rhodium complexes with bidentate glycosyl heterocyclic ligands induce cytostasis in platinum-resistant ovarian cancer cells and bacteriostasis in Gram-positive multiresistant bacteria
István Kacsir, Adrienn Sipos, Tímea Kiss, et al.
Frontiers in Chemistry (2023) Vol. 11
Open Access | Times Cited: 9
Polysaccharides from marine resources exhibit great potential in the treatment of tumor: A review
Hao Ju, Yu Chong, Wei Liu, et al.
Carbohydrate Polymer Technologies and Applications (2023) Vol. 5, pp. 100308-100308
Open Access | Times Cited: 9
In silico anti-cancer activity evaluation of C−N cyclometalated 2H-indazole Ru(II) and Ir(III) complexes via induced DNA disrupting potential
Thimma Subramanian Prathima, Kaushik Chanda, Balamurali MM
Inorganica Chimica Acta (2024) Vol. 567, pp. 122038-122038
Closed Access | Times Cited: 2
Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound
Nazia Nayeem, Sami Sauma, Afruja Ahad, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 5, pp. 1364-1376
Closed Access | Times Cited: 2
Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model
Kirill Miachin, Virginia del Solar, Elsy El Khoury, et al.
Inorganic Chemistry (2021) Vol. 60, Iss. 24, pp. 19152-19164
Open Access | Times Cited: 18
Ruthenium Half-Sandwich Type Complexes with Bidentate Monosaccharide Ligands Show Antineoplastic Activity in Ovarian Cancer Cell Models through Reactive Oxygen Species Production
István Kacsir, Adrienn Sipos, Gyula Ujlaki, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10454-10454
Open Access | Times Cited: 17
Ru(III) Complexes with Lonidamine-Modified Ligands
Ilya A. Shutkov, Yulia N. Okulova, V. Yu. Tyurin, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13468-13468
Open Access | Times Cited: 16
Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100
Brian Park, Paromita Raha, Jim Pankovich, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 28-28
Open Access | Times Cited: 9
RuII and RuIII complexes with 2,6-di-tert-butylphenol ligands: synthesis, electrochemical behaviour, antioxidant properties and antiproliferative activity
Anastasia A. Antonets, Ksenia M. Voroshilkina, Ilya A. Shutkov, et al.
Mendeleev Communications (2024) Vol. 34, Iss. 1, pp. 74-77
Open Access | Times Cited: 1
From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs
Srividya Swaminathan, Jebiti Haribabu, Ramasamy Karvembu
ChemMedChem (2024)
Open Access | Times Cited: 1
New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
Ilya A. Shutkov, Yulia N. Okulova, Dmitrii M. Mazur, et al.
Pharmaceutics (2023) Vol. 15, Iss. 5, pp. 1366-1366
Open Access | Times Cited: 4
ER Stress Response and Induction of Apoptosis in Malignant Pleural Mesothelioma: The Achilles Heel Targeted by the Anticancer Ruthenium Drug BOLD-100
Elia Ranzato, Gregorio Bonsignore, Simona Martinotti
Cancers (2022) Vol. 14, Iss. 17, pp. 4126-4126
Open Access | Times Cited: 6
The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity
Daniel S. Labach, Hinissan P. Kohio, Edwin A. Tse, et al.
Biomolecules (2023) Vol. 13, Iss. 7, pp. 1095-1095
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top